Bora Pharmaceuticals Announces Multi-Year Expansion for Midwest Manufacturing Site, as Upsher-Smith Entity Split is Finalized
'Bora's Maple Grove facility offers a unique opportunity for large pharmaceutical innovators to secure space in a state-of-the-art site staffed by experts in formulation development, tech transfer, and commercial manufacturing,' said J.D. Mowery.
As the entity separation from Upsher-Smith Laboratories takes effect on August 5, Bora continues its growth amid surging demand for oral solid dose (OSD) development and manufacturing brought on by increasingly complex formulations, novel drug delivery technologies, and the growing shift of biologics into OSD formats. Bora has already secured multiple multi-million-dollar contracts for development and commercial supply of advanced OSD programs.
'With pharmaceutical companies relying more heavily on specialized CDMO partners to scale production and maintain quality, top-tier manufacturing capacity and technical expertise are at a premium,' said J.D. Mowery, president of Bora's CDMO business. 'Bora's Maple Grove facility offers a unique opportunity for innovators to secure space in a state-of-the-art site staffed by experts in formulation development, tech transfer, and commercial manufacturing.'
The first phase of Bora's investment will add a Gerteis Macro-Pactor® at the company's state-of-the-art site. This investment initiates a broader buildout of 100,000 square feet of dedicated shell space designed to streamline production for partners with high-volume needs.
The Gerteis Macro-Pactor® roller compactor will be installed and operational in the third quarter of 2025.
'As we complete our transition from Upsher-Smith, we're creating the infrastructure to deliver integrated manufacturing, packaging, and analytical services with the speed and quality our clients need,' shared Dennis Hall, Vice President and General Manager of the Maple Grove site. 'As we expand our capabilities, we look forward to tapping into all the experience and talent in the area.'
The facility offers on-site quality control laboratories and a dedicated development team to support product and analytical development as well as innovation. It is an FDA-inspected manufacturing site and meets global health authority requirements, ensuring regulatory compliance.
From early development and scale-up to process optimization and commercial manufacturing, Bora's experienced teams support customers at every stage of the product lifecycle. The company's commercial on-time, in-full (OTIF) delivery record is unmatched, reinforcing Bora's role as a trusted partner, supporting clients with secure, consistent supply. For more information, visit boracdmo.com
About Bora Pharmaceuticals
Bora Pharmaceuticals is a premier international contract development and manufacturing organization (CDMO) specializing in formulation development, clinical and commercial manufacturing, and packaging of complex oral solid dose, liquid, semi-solid, biologics, and sterile injectable pharmaceutical products. From our world-class sites in North America and Asia, we deliver drug products with unparalleled quality to more than 100 markets around the world. For more information, visit www.boracdmo.com.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Upturn
an hour ago
- Business Upturn
Radware Reports DDoS Attack Volumes in APAC Rise 364%
TOKYO, Aug. 07, 2025 (GLOBE NEWSWIRE) — Radware® (NASDAQ: RDWR), a global leader in application security and delivery solutions for multi-cloud environments, released threat intelligence findings that offer a year-over-year look at the rise in cyber activity in the APAC region. Radware's threat intelligence is based on 2024 network and application attack activity sourced from the company's cloud and managed services, and threat intelligence research team. In addition, it draws from information found on Telegram, a public messaging platform often used by cybercriminals. Key findings Between 2023 and 2024 in APAC: Average mitigated DDoS attack volumes rose 364%. The number of DNS flood queries rose 93%. Government institutions were the top hacktivist targets, followed by education. 'Across APAC, there has been a sharp escalation in the frequency and intensity of cyberattacks and DDoS incidents are leading the charge,' said Kenichiro Sasaki, Radware's county manager in Japan. 'Multiple catalysts are driving the threat revolution, including geopolitical conflicts, bigger and more complex threat surfaces, and more sophisticated and persistent threats. Add to that the impact of AI, which is lowering barriers to entry, and what you have is a highly dynamic threat environment that demands equally dynamic defense strategies.' Network-layer DDoS attacks grow three times bigger In 2024, network DDoS attack activity and intensity witnessed a significant uptick in APAC. According to Radware's threat intelligence: Attack activity : The average number of DDoS attacks per customer increased 72% compared to 2023. : The average number of DDoS attacks per customer increased 72% compared to 2023. Attack volume: The average mitigated DDoS attack volume climbed 364% over 2023. The average mitigated DDoS attack volume climbed 364% over 2023. Industry targets : Services providers bore 55% of the network DDoS attack volume, followed by technology at 21% and gaming at 11%. Application-layer DNS DDoS attacks post major gains Last year was a pivotal year in the global evolution of Layer 7 DNS DDoS attacks. During 2024 in APAC: Attack activity: The number of DNS flood queries rose 93% compared to 2023. The number of DNS flood queries rose 93% compared to 2023. Attack volume: Malicious DNS volume increased 93% over 2023. Malicious DNS volume increased 93% over 2023. Industry targets: The manufacturing sector accounted for 43% of malicious DNS Query Flood activity. Telecom (40%) ranked second, followed by energy (14%). Hacktivist campaigns intensify, marked by retaliation and disruption Propelled by political and ideological tensions, hacktivism remained a leading driver of cyberattacks. On a global basis, the total number of hacktivist-claimed DDoS attacks increased by 20% between 2023 and 2204, according to data gathered from Telegram. Across APAC, 2024 Telegram data revealed: Geographic targets: The top targeted country was India with 761 claimed attacks, followed by Indonesia (614), Taiwan (281), Thailand (220), and Bangladesh (188). The top targeted country was India with 761 claimed attacks, followed by Indonesia (614), Taiwan (281), Thailand (220), and Bangladesh (188). Industry targets: Government institutions were the top hacktivist targets, accounting for 17% of hacktivist activity, followed by education (12%) and finance (9%). Government institutions were the top hacktivist targets, accounting for 17% of hacktivist activity, followed by education (12%) and finance (9%). Top claiming actors: Executor DDoS was the most prolific threat actor with 513 claimed DDoS attacks, followed by RipperSec (467), and NoName057(16) (362). A comprehensive global view of the threat landscape can be found in Radware's new 2025 Global Threat Analysis Report. About Radware Radware® (NASDAQ: RDWR) is a global leader in application security and delivery solutions for multi-cloud environments. The company's cloud application, infrastructure, and API security solutions use AI-driven algorithms for precise, hands-free, real-time protection from the most sophisticated web, application, and DDoS attacks, API abuse, and bad bots. Enterprises and carriers worldwide rely on Radware's solutions to address evolving cybersecurity challenges and protect their brands and business operations while reducing costs. For more information, please visit the Radware website. Radware encourages you to join our community and follow us on: Facebook, LinkedIn, Radware Blog, X, and YouTube. ©2025 Radware Ltd. All rights reserved. Any Radware products and solutions mentioned in this press release are protected by trademarks, patents, and pending patent applications of Radware in the U.S. and other countries. For more details, please see: All other trademarks and names are property of their respective owners. THIS PRESS RELEASE AND THE RADWARE 2025 GLOBAL THREAT ANALYSIS REPORT ARE PROVIDED FOR INFORMATIONAL PURPOSES ONLY. THESE MATERIALS ARE NOT INTENDED TO BE AN INDICATOR OF RADWARE'S BUSINESS PERFORMANCE OR OPERATING RESULTS FOR ANY PRIOR, CURRENT, OR FUTURE PERIOD. Radware believes the information in this document is accurate in all material respects as of its publication date. However, the information is provided without any express, statutory, or implied warranties and is subject to change without notice. The contents of any website or hyperlinks mentioned in this press release are for informational purposes and the contents thereof are not part of this press release. Safe Harbor Statement This press release includes 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements made herein that are not statements of historical fact, including statements about Radware's plans, outlook, beliefs, or opinions, are forward-looking statements. Generally, forward-looking statements may be identified by words such as 'believes,' 'expects,' 'anticipates,' 'intends,' 'estimates,' 'plans,' and similar expressions or future or conditional verbs such as 'will,' 'should,' 'would,' 'may,' and 'could.' For example, when we say in this press release that the impact of AI, which is lowering barriers to entry, causes a highly dynamic threat environment, we are using forward-looking statements. Because such statements deal with future events, they are subject to various risks and uncertainties, and actual results, expressed or implied by such forward-looking statements, could differ materially from Radware's current forecasts and estimates. Factors that could cause or contribute to such differences include, but are not limited to: the impact of global economic conditions, including as a result of the state of war declared in Israel in October 2023 and instability in the Middle East, the war in Ukraine, tensions between China and Taiwan, financial and credit market fluctuations (including elevated interest rates), impacts from tariffs or other trade restrictions, inflation, and the potential for regional or global recessions; our dependence on independent distributors to sell our products; our ability to manage our anticipated growth effectively; our business may be affected by sanctions, export controls, and similar measures, targeting Russia and other countries and territories, as well as other responses to Russia's military conflict in Ukraine, including indefinite suspension of operations in Russia and dealings with Russian entities by many multi-national businesses across a variety of industries; the ability of vendors to provide our hardware platforms and components for the manufacture of our products; our ability to attract, train, and retain highly qualified personnel; intense competition in the market for cybersecurity and application delivery solutions and in our industry in general, and changes in the competitive landscape; our ability to develop new solutions and enhance existing solutions; the impact to our reputation and business in the event of real or perceived shortcomings, defects, or vulnerabilities in our solutions, if our end-users experience security breaches, or if our information technology systems and data, or those of our service providers and other contractors, are compromised by cyber-attackers or other malicious actors or by a critical system failure; our use of AI technologies that present regulatory, litigation, and reputational risks; risks related to the fact that our products must interoperate with operating systems, software applications and hardware that are developed by others; outages, interruptions, or delays in hosting services; the risks associated with our global operations, such as difficulties and costs of staffing and managing foreign operations, compliance costs arising from host country laws or regulations, partial or total expropriation, export duties and quotas, local tax exposure, economic or political instability, including as a result of insurrection, war, natural disasters, and major environmental, climate, or public health concerns; our net losses in the past and the possibility that we may incur losses in the future; a slowdown in the growth of the cybersecurity and application delivery solutions market or in the development of the market for our cloud-based solutions; long sales cycles for our solutions; risks and uncertainties relating to acquisitions or other investments; risks associated with doing business in countries with a history of corruption or with foreign governments; changes in foreign currency exchange rates; risks associated with undetected defects or errors in our products; our ability to protect our proprietary technology; intellectual property infringement claims made by third parties; laws, regulations, and industry standards affecting our business; compliance with open source and third-party licenses; complications with the design or implementation of our new enterprise resource planning ('ERP') system; our reliance on information technology systems; our ESG disclosures and initiatives; and other factors and risks over which we may have little or no control. This list is intended to identify only certain of the principal factors that could cause actual results to differ. For a more detailed description of the risks and uncertainties affecting Radware, refer to Radware's Annual Report on Form 20-F, filed with the Securities and Exchange Commission (SEC), and the other risk factors discussed from time to time by Radware in reports filed with, or furnished to, the SEC. Forward-looking statements speak only as of the date on which they are made and, except as required by applicable law, Radware undertakes no commitment to revise or update any forward-looking statement in order to reflect events or circumstances after the date any such statement is made. Radware's public filings are available from the SEC's website at or may be obtained on Radware's website at . Media Contact:Gerri DyrekRadware [email protected]
Medscape
2 hours ago
- Medscape
FDA Approves Drug for Aggressive Glioma
The FDA has granted accelerated approval to dordaviprone (Modeyso, Jazz Pharmaceuticals) for H3 K27M-mutant diffuse glioma, marking the first time a systemic therapy has been approved for the aggressive glioma subtype. H3 K27M-mutant diffuse glioma is a grade 4 midline tumor that primarily affects children and young adults. Median survival is about a year. Historically, treatment has been limited to radiation, with few options available after recurrence besides palliative care. Dordaviprone is a first-in-class oral imipridone that disrupts tumor cell metabolism and increases tumor susceptibility to immune-mediated attack. Jazz Pharmaceuticals bought Chimerix in early 2025 for almost $1 billion based on dordaviprone's commercial prospects. 'Dordaviprone has the potential to rapidly become a standard of care for a rare oncology disease and also contribute durable revenue beginning in the near-term,' Jazz CEO Bruce Cozadd, said in a press release at the time. Approval was based on a pooled analysis of five single-arm studies enrolling 46 adults and four children with recurrent tumors previously treated with radiation, according to a statement from the FDA. Adults received 625 mg once weekly while pediatric patients received lower, weight-adjusted weekly doses. Mutation status was confirmed by immunohistochemistry or sequencing of archival tumor tissue. The overall response rate was 22%. The median time to response was 8.3 months, and the median duration of response (DOR) was 10.3 months. Among 11 patients with objective responses, 73% had a DOR of at least 6 months, and 27% had a DOR of at least 12 months. Seven of 15 evaluable patients (46.7%) were able to have corticosteroid dose reductions of at least 50%, and performance status improved in six of 34 (20.6%) patients. Sixty percent of subjects experienced treatment-related, treatment-emergent adverse events (TR-TEAEs), including fatigue (34%), nausea (18%), decreased lymphocyte levels (14%). The most common serious adverse events were hydrocephalus (8%) and nausea (8%). Grade 3 TR-TEAEs occurred in 20%, most commonly fatigue (10%). One case each of seizure and pulmonary embolism were seen. There were no treatment-related deaths. The drug's prescribing information includes warnings and precautions for hypersensitivity, QTc interval prolongation, and embryo-fetal toxicity, according to the FDA statement. A phase 3 trial is underway to confirm the benefit of dordaviprone for recurrent H3 K27M-mutant diffuse glioma. M. Alexander Otto is a physician assistant with a master's degree in medical science and a journalism degree from Newhouse. He is an award-winning medical journalist who worked for several major news outlets before joining Medscape. Alex is also an MIT Knight Science Journalism fellow. Email: aotto@
Business Wire
4 hours ago
- Business Wire
FlexGen Expands Global Battery Energy Storage Leadership with Court Approval of Powin Assets Acquisition
DURHAM, N.C.--(BUSINESS WIRE)--FlexGen Power Systems, LLC ('FlexGen'), a leading provider of battery energy storage solutions and energy management software, today announced that the U.S. Bankruptcy Court for the District of New Jersey, the Court presiding over the Chapter 11 cases of Powin, LLC and Powin affiliates, has approved FlexGen's acquisition of a substantial portion of Powin's business, advancing FlexGen's mission to future proof global grids and growing energy demand through battery energy storage. 'This is a significant milestone, not just for FlexGen, but for the entire industry, as storage is no longer a nice-to-have, but rather, essential to meeting global energy demand and opportunities,' said FlexGen CEO, Kelcy Pegler. Share Through the acquisition, FlexGen will own all of Powin's IP, including hardware IP, software IP and information technology systems, along with a significant spare parts inventory. Upon closing of the acquisition, FlexGen will support over 25 GWh of battery energy storage systems and 200 projects across 10 countries in its portfolio. FlexGen's Remote Operations Center (ROC) will gain system visibility to ensure continuity for Powin customers, while its FlexGen HybridOS® controls software, analytics modules and lifecycle services will be made available to provide additional insights and best-in-class system availability. 'This is a significant milestone, not just for FlexGen, but for the entire industry, as storage is no longer a nice-to-have, but rather, essential to meeting global energy demand and opportunities,' said FlexGen CEO, Kelcy Pegler. 'With this acquisition, we will continue to deliver the reliability and intelligence the grid, data centers and communities need to thrive in a world of growing energy needs.' Drawing on 15 years of integration experience with over 65 configurations from 22 global vendors, FlexGen is prepared to deliver immediate continuity and support for Powin customers. With its full suite of lifecycle services and hardware-agnostic FlexGen HybridOS® software products, FlexGen meets operators where they are today while driving an AI-centric roadmap for its analytics module and sophisticated controls software. The impact is futureproofing customer investments with maximum uptime and minimal disruption. 'Our top priority is customer success and delivering immediate operational stability, maximizing the value and performance of their systems. FlexGen's proven financial strength means we're a capital-light software and services partner that will remain in business to deliver on our customer promises,' added Gary Cristini, FlexGen's CFO. 'We thank Powin for their early-mover role in shaping the dynamic and important grid-scale battery market and honor our commitment to carry on that legacy and deliver exceptional uptime, reliability and customer success.' For more information about FlexGen and this transition, visit: If you're an existing Powin customer with questions, please reach out to: PowinSupport@ About FlexGen Power Systems, LLC. FlexGen provides industry-leading software and services for deploying, managing and optimizing battery energy storage systems. FlexGen leverages decades of software, engineering, and procurement expertise to solve today's toughest energy challenges that enable the transition to a modern electric grid. FlexGen HybridOS® energy management software seamlessly integrates with any battery OEM and offers advanced analytics and AI-driven insights that allow energy storage owners to deploy diverse power market strategies and integrate various generation forms, enhancing grid stability and economic returns. Serving more than 25 GWh and over 200 energy storage systems enabled by FlexGen, we are trusted by the most technically and commercially demanding developers, utilities, government agencies, and industrial companies in the world.
